Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets

被引:18
作者
Lories, RJU [1 ]
Luyten, FP [1 ]
机构
[1] Univ Hosp Leuven, Dept Rheumatol, Lab Skeletal Dev & Joint Disorders, B-3000 Leuven, Belgium
关键词
arthritis; osteoclast; osteopetrosis; osteoporosis; osteoprotegerin; osterprotegerin-ligand/RANK-ligand; RANK;
D O I
10.1007/s100670170095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoprotegerin-ligand, also called Osteoclast Differentiation Factor or RANK-ligand, its receptor RANK and its decoy receptor Osteoprotegerin are key molecules regulating osteoclast differentiation and activation. In this view we discuss structure and expression of these molecules, the genetic models addressing their function and their role in in vivo models of osteoclast differentiation and activation. The new paradigm that has evolved from these studies, is not only important in normal bone homeostasis but also appears to play a role in different diseases that affect the skeleton, such as osteoporosis, inflammatory joint disease and cancer. It has opened a new era in bone research by increasing our molecular knowledge and providing new therapeutic targets in bone disease.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 37 条
[1]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[3]  
Capparelli C, 2000, CANCER RES, V60, P783
[4]   RANK is essential for osteoclast and lymph node development [J].
Dougall, WC ;
Glaccum, M ;
Charrier, K ;
Rohrbach, K ;
Brasel, K ;
De Smedt, T ;
Daro, E ;
Smith, J ;
Tometsko, ME ;
Maliszewski, CR ;
Armstrong, A ;
Shen, V ;
Bain, S ;
Cosman, D ;
Anderson, D ;
Morrissey, PJ ;
Peschon, JJ ;
Schuh, J .
GENES & DEVELOPMENT, 1999, 13 (18) :2412-2424
[5]   TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts [J].
Fuller, K ;
Wong, B ;
Fox, S ;
Choi, YW ;
Chambers, TJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (05) :997-1001
[6]  
Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO
[7]  
2-P
[8]   Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis [J].
Hofbauer, LC ;
Gori, F ;
Riggs, BL ;
Lacey, DL ;
Dunstan, CR ;
Spelsberg, TC ;
Khosla, S .
ENDOCRINOLOGY, 1999, 140 (10) :4382-4389
[9]   Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells [J].
Hofbauer, LC ;
Lacey, DL ;
Dunstan, CR ;
Spelsberg, TC ;
Riggs, BL ;
Khosla, S .
BONE, 1999, 25 (03) :255-259
[10]   Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines [J].
Hofbauer, LC ;
Dunstan, CR ;
Spelsberg, TC ;
Riggs, BL ;
Khosla, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (03) :776-781